Q4 2021 13F Holders as of 12/31/2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
70.9M
-
Number of holders
-
114
-
Total 13F shares, excl. options
-
34.9M
-
Shares change
-
+14.9K
-
Total reported value, excl. options
-
$1.12B
-
Value change
-
-$4.99M
-
Number of buys
-
53
-
Number of sells
-
-47
-
Price
-
$32.20
Significant Holders of C4 Therapeutics, Inc. - Common Stock (CCCC) as of Q4 2021
131 filings reported holding CCCC - C4 Therapeutics, Inc. - Common Stock as of Q4 2021.
C4 Therapeutics, Inc. - Common Stock (CCCC) has 114 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 34.9M shares
of 70.9M outstanding shares and own 49.27% of the company stock.
Largest 10 shareholders include PRICE T ROWE ASSOCIATES INC /MD/ (4.08M shares), BlackRock Inc. (3.41M shares), RTW INVESTMENTS, LP (2.49M shares), PERCEPTIVE ADVISORS LLC (2.21M shares), VANGUARD GROUP INC (2.02M shares), ArrowMark Colorado Holdings LLC (1.77M shares), Bain Capital Life Sciences Investors, LLC (1.64M shares), STATE STREET CORP (1.59M shares), RA CAPITAL MANAGEMENT, L.P. (1.38M shares), and WASATCH ADVISORS INC (1.3M shares).
This table shows the top 114 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.